Trastuzumab deruxtecan for HER2-expressing metastatic colorectal cancer

被引：0
作者：
Baker, Holly
机构：
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2021年 / 6卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [31] A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
    Siena, Salvatore
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Fakih, Marwan
    Elez, Elena
    Rodriguez, Javier
    Ciardiello, Fortunato
    Saxena, Kapil
    Yamamoto, Eriko
    Bako, Emarjola
    Okuda, Yasuyuki
    Shahidi, Javad
    Grothey, Axel
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
    Oaknin, Ana
    Lee, Jung-Yun
    Makker, Vicky
    Oh, Do-Youn
    Banerjee, Susana
    Gonzalez-Martin, Antonio
    Jung, Kyung Hae
    Lugowska, Iwona
    Manso, Luis
    Manzano, Aranzazu
    Melichar, Bohuslav
    Siena, Salvatore
    Stroyakovskiy, Daniil
    Fielding, Anitra
    Puvvada, Soham
    Smith, Ann
    Meric-Bernstam, Funda
    ADVANCES IN THERAPY, 2024, 41 (11) : 4125 - 4139
  • [33] Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
    Indini, Alice
    Rijavec, Erika
    Grossi, Francesco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (09)
  • [34] Fam-Trastuzumab Deruxtecan in HER2/Neu-Expressing Serous Endometrial Cancer
    Rose, Peter G.
    Kelley, Johanna A.
    Feldman, Myra
    Krivanek, Kevin
    JCO PRECISION ONCOLOGY, 2023, 7
  • [35] Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer
    Dickerson, James
    Moen, Marcus
    Nielsen, Perry
    Tran, Edward
    Suen, Wesley
    Goldhaber-Fiebert, Jeremy D.
    Alarid-Escudero, Fernando
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] A PHASE 1/2 STUDY OF SBT6050 COMBINED WITH TRASTUZUMAB DERUXTECAN (T-DXD) OR TRASTUZUMAB AND TUCATINIB WITH OR WITHOUT CAPECITABINE IN PATIENTS WITH HER2-EXPRESSING OR HER2-AMPLIFIED CANCERS
    Klempner, Samuel
    Strickler, John
    Gourley, Lindsey
    Jacquemont, Celine
    Bhatia, Vinona
    Hunder, Naomi
    Odegard, Valerie
    Piha-Paul, Sarina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A426 - A426
  • [37] Trastuzumab deruxtecan for HER2+advanced breast cancer
    Lee, Jiyun
    Park, Yeon Hee
    FUTURE ONCOLOGY, 2021, 18 (01) : 7 - 19
  • [38] Trastuzumab and lapatinib in HER2-positive metastatic colorectal cancer
    Biswas, Bivas
    Rastogi, Sameer
    Batra, Atul
    Ganguly, Sandip
    NATIONAL MEDICAL JOURNAL OF INDIA, 2016, 29 (04) : 219 - 220
  • [39] Photoimmunotherapy of HER2-expressing Breast Cancer Cells
    Klemenz, Lukas
    Wolf, Isis
    Storz, Jonas
    Schultze-seemann, Susanne
    Gratzke, Christian
    Lauw, Susan
    Brueckner, Reinhard
    Wolf, Philipp
    CANCER GENOMICS & PROTEOMICS, 2024, 21 (04) : 361 - 367
  • [40] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)
    Yoshino, Takayuki
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Wainberg, Zev A.
    Elez, Elena
    Rodriguez, Javier
    Fakih, Marwan
    Ciardiello, Fortunato
    Saxena, Kapil
    Kobayashi, Kojiro
    Bako, Emarjola
    Okuda, Yasuyuki
    Meinhardt, Gerold
    Grothey, Axel
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345